Cargando…
Asciminib in chronic myeloid leukemia: a STAMP for expedited delivery?
Asciminib is a novel tyrosine kinase inhibitor (TKI) that specifically targets the myristoyl pocket. It has increased selectivity and potent activity against BCR-ABL1 and the mutants that most frequently prevent the activity of the ATP-binding competitive inhibitors. Results for clinical trials in p...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Fondazione Ferrata Storti
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620583/ https://www.ncbi.nlm.nih.gov/pubmed/37102603 http://dx.doi.org/10.3324/haematol.2022.282361 |